https://www.mypharma-editions.com/oncologie-precision-biosciences-et-servier-etendent-leur-collaboration-de-developpement-de-car-t
Oncologie : Precision BioSciences et Servier étendent leur collaboration de développement de CAR-T...
Sep 18, 2020 - Servier et Precision BioSciences, une société biotechnologique développant des traitements par correction génique in vivo et à base de cellules CAR T...
precision biosciencesoncologieservierleurcollaboration
https://precisionbiosciences.com/hbv/
Chronic Hepatitis B (HBV) - Precision BioSciences
chronic hepatitis bprecision bioscienceshbv
https://www.smithlaw.com/newsroom/news/Precision-BioSciences-Completes-110M-Preferred-Stock-Financing-to-Advance-Genome-Editing-Programs
Precision BioSciences Completes $110M Preferred Stock Financing to Advance Genome Editing Programs
A team of Smith Anderson lawyers advised client Precision BioSciences in its $110 million preferred stock financing to further product development efforts for...
precision biosciencespreferred stockgenome editingcompletesfinancing
https://www.tiva.bio/news/the-power-of-precision-cd8-tlnps
The Power of Precision CD8+ tLNPs | Tiva Biosciences | Targeted LNP Delivery Service
CD8 Targeted Lipid Nanoparticle Validation
the powerdelivery serviceprecisiontivabiosciences
https://dmdwarrior.com/tr/precision-biosciences-anticipates-beginning-patient-dosing-for-duchenne-muscular-dystrophy-in-the-early-second-quarter-of-2026/
Precision BioSciences, Duchenne Musküler Distrofisi Hastalarına Doz Uygulamasına 2026 Yılının...
Jan 12, 2026 - DMD programı PBGENE-DMD için, Precision BioSciences, beklenen sonuçların ardından 2026 yılının ilk çeyreğinin sonlarında veya ikinci çeyreğinin başlarında...
precision biosciencesduchennedoz
https://dmdwarrior.com/ar/the-fda-designates-pbgene-dmd-as-an-orphan-drug-by-precision-biosciences-to-treat-duchenne-muscular-dystrophy/
FDA يصنف PBGENE-DMD كدواء يتيم بواسطة Precision BioSciences لعلاج ضمور العضلات دوشين
Jul 23, 2025 - Precision BioSciences، وهي شركة لتحرير الجينات في المرحلة السريرية تستخدم منصة ARCUS® الجديدة الخاصة بها لتطوير علاجات تحرير الجينات في الجسم الحي
precision biosciencesfdadmd